ID   SMS-SAN
AC   CVCL_7136
SY   sms-SAN; SMS SAN
DR   cancercelllines; CVCL_7136
DR   Cosmic; 717428
DR   Cosmic; 848933
DR   Cosmic; 1019951
DR   Cosmic; 1162008
DR   Cosmic; 1890107
DR   GEO; GSM2371261
DR   GEO; GSM2394374
DR   GEO; GSM3145731
DR   Wikidata; Q54954998
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1016/B978-0-12-008304-6.50015-4;
RX   PubMed=3456456;
RX   PubMed=7037175;
RX   PubMed=11507071;
RX   PubMed=15390183;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=18724359;
RX   PubMed=23202128;
RX   PubMed=24792489;
RX   PubMed=28350380;
WW   http://www.cccells.org/dl/NB_Data_Sheets/SMS-SAN_Cell_Line_Data_Sheet_COGcell_org.pdf
CC   Doubling time: ~71 hours (PubMed=3456456).
CC   Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (PubMed=18724359; PubMed=28350380).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Pro252fs*144 (c.753_763del11); Zygosity=Unspecified (PubMed=23202128).
CC   Omics: Array-based CGH.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): COG
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 12
ST   D18S51: 16,19
ST   D19S433: 13,14
ST   D21S11: 29,31.2
ST   D2S1338: 19
ST   D3S1358: 15,17
ST   D5S818: 11
ST   D7S820: 8,11
ST   D8S1179: 10,11
ST   FGA: 19
ST   TH01: 6,9.3
ST   TPOX: 8,12
ST   vWA: 17,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_AQ29 ! SMS-SAL
SX   Female
AG   3Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 26
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999).
//
RX   DOI=10.1016/B978-0-12-008304-6.50015-4;
RA   Biedler J.L., Meyers M.B., Spengler B.A.;
RT   "Homogeneously staining regions and double minute chromosomes,
RT   prevalent cytogenetic abnormalities of human neuroblastoma cells.";
RL   (In book chapter) Advances in cellular neurobiology, Vol. 4; Fedoroff S., Hertz L. (eds.); pp.267-307; Academic Press; New York; USA (1983).
//
RX   PubMed=3456456; DOI=10.1093/jnci/76.3.375;
RA   Reynolds C.P., Biedler J.L., Spengler B.A., Reynolds D.A., Ross R.A.,
RA   Frenkel E.P., Smith R.G.;
RT   "Characterization of human neuroblastoma cell lines established before
RT   and after therapy.";
RL   J. Natl. Cancer Inst. 76:375-387(1986).
//
RX   PubMed=7037175;
RA   Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.;
RT   "Selective toxicity of 6-hydroxydopamine and ascorbate for human
RT   neuroblastoma in vitro: a model for clearing marrow prior to
RT   autologous transplant.";
RL   Cancer Res. 42:1331-1336(1982).
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//
RX   PubMed=15390183; DOI=10.1002/gcc.20096;
RA   Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.;
RT   "Expression profiles and clinical relationships of ID2, CDKN1B, and
RT   CDKN2A in primary neuroblastoma.";
RL   Genes Chromosomes Cancer 41:297-308(2004).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K.A., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177; PMCID=PMC1533846;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=18724359; DOI=10.1038/nature07261; PMCID=PMC2672043;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493; PMCID=PMC3557959;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33; PMCID=PMC5369315;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//